Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-25
2005-10-25
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S255000
Reexamination Certificate
active
06958343
ABSTRACT:
Compounds of formula (I):are described herein. The compounds can be used, for example, in the treatment of chemokine mediated diseases, including inflammatory diseases such as psoriasis and COPD.
REFERENCES:
patent: 2924472 (1960-02-01), Bush
patent: 3318900 (1967-05-01), Janssen
patent: 3445120 (1969-05-01), Barr
patent: 4061459 (1977-12-01), Parmann
patent: 4126689 (1978-11-01), Sanczuk et al.
patent: 4188040 (1980-02-01), Wolf et al.
patent: 4213619 (1980-07-01), Arlt et al.
patent: 4234199 (1980-11-01), Moncaster et al.
patent: 4278677 (1981-07-01), Nedelec et al.
patent: 4410528 (1983-10-01), Teranishi et al.
patent: 4483544 (1984-11-01), Faerber et al.
patent: 4641858 (1987-02-01), Roux
patent: 5064207 (1991-11-01), Bengtsson
patent: 5169161 (1992-12-01), Jones
patent: 5297824 (1994-03-01), Imhof et al.
patent: 5521197 (1996-05-01), Audia
patent: 5599028 (1997-02-01), Neumann et al.
patent: 5988695 (1999-11-01), Corbett, Jr.
patent: 6142484 (2000-11-01), Valls, Jr.
patent: 6172067 (2001-01-01), Ito et al.
patent: 6248755 (2001-06-01), Chapman et al.
patent: 6329381 (2001-12-01), Kurimoto et al.
patent: 6407121 (2002-06-01), Nagamine et al.
patent: 6432981 (2002-08-01), Finke et al.
patent: 2003/0176693 (2003-09-01), Tsushima et al.
patent: 2331223 (1974-01-01), None
patent: 41 19 767 (1992-12-01), None
patent: 0 293 078 (1988-11-01), None
patent: 0 447 324 (1991-09-01), None
patent: 0778277 (1997-06-01), None
patent: 1 069 124 (2001-01-01), None
patent: 1 122 257 (2001-08-01), None
patent: 2359079 (2001-08-01), None
patent: 51-88994 (1976-08-01), None
patent: WO 97/40035 (1997-10-01), None
patent: WO 98/08847 (1998-03-01), None
patent: WO 98/25617 (1998-06-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 99/17773 (1999-04-01), None
patent: WO 99/36421 (1999-07-01), None
patent: WO99/51608 (1999-10-01), None
patent: WO 00/08013 (2000-02-01), None
patent: WO 00/09511 (2000-02-01), None
patent: WO 00/38680 (2000-07-01), None
patent: WO 00/39129 (2000-07-01), None
patent: WO 00/45800 (2000-08-01), None
patent: WO 00/59502 (2000-10-01), None
patent: WO 00/76514 (2000-12-01), None
patent: WO 01/19825 (2001-03-01), None
patent: WO 01/25200 (2001-04-01), None
patent: WO 01/25242 (2001-04-01), None
patent: WO 01/25242 (2001-04-01), None
patent: WO 01/58902 (2001-08-01), None
patent: WO 01/58906 (2001-08-01), None
patent: WO 01/62758 (2001-08-01), None
patent: WO 01/6525 (2001-09-01), None
patent: WO 02/083693 (2002-10-01), None
patent: WO 03/024966 (2003-03-01), None
Trivedi, B.K. et al, Ann. Reports Med. Chem., vol. 35, 2000, pp. 191-200.
West, Anthony R., “Solid State Chemistry and its Applications,” Wiley, New York, 1988, pp. 358 & 365.
STN International, file CAPLUS, CAPLUS accession No. 1996: 243961, document No. 125: 10744, Gewald, K. et al.: “New Synthesis of substituted 4-aminoquinazolines and their hetero analogs”, J. Prakt. Chem./Chem.-Ztg.,338 (3) 206-213 (1996).
Ahmed et al., “Novel synthesis of 1-aryl-9-alkyl-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[2,3-b]quinoxalines by lithium aluminum hydride reduction of N-phenyl-1-benzimidazolylsuccinimides”, CAPLUS 79:92106 (1973).
Chemical Abstracs, vol. 54, No. 10, May 1960, Abstract No. 9933f, C. Wayne Noell and Roland K. Robins, “Potential Purine Antagonists XVII. Synthesis of 2-methyl and 2-methylthio-6, 8-disubstituted purines”, see formula III when R-SMe,R1=C1, R2=OH.
Cohen et al., “Cytokine function: A study in biologic diversity”, CAPLUS 125:31527 (1996).
Cowley et al., “Preparation of 1-(3-phenyloxypropyl)piperdine derivatives as opioid receptor ligands”, CAPLUS 138:39189 (2002).
Finke et al., “Preparation of pipeidinylmethylcyclopentanes as modulators of CCR-5 and/or CCR-3 chemokine receptors”, CAPLUS 134:56576 (2000) CAS Listing, 77 answers.
Fukuda et al., “Preparation of benzotriazole derivatives as cardiovascular agents and antipsychotics”, CAPLUS 123:340149 (1995).
Grant, “University of Minnesota-Twin Cities Campus College of Pharmacy, Annual Report”, [online] 1999, [retrieve on Feb. 13, 2003]. Retrieved from the internet, http://www.msl.umn.edu/general/Reports/ar99/departments/pharmacy.html.
Kiriasis et al., “Synthesis and Properties of New Pteridine Nucleosides”,Dev. Biochem. 4:49-53 (1978).
McNaught et al., “IUPAC Compendium of Chemical Terminology, 2ndEd” (1997).
Ott et al., “4-amino-7, 8-dihydro-2-(methylmercapto)-8-β, -D-ribofuranosylpteridin-7-One. Modified Fusion Reaction with Trimethylsilylated Pteridine Derivatives”,Nucl. Acid. Chem. 2:735-739 (1978).
Ott et al., “Zur Synthese des 4-Amino-7-oxo-7, 8-dihydropteridin-N-8-β-D-ribofuranosids—ein strukturanaloges Nucleosid des Adenosins”,Chem. Ber. 107:339-361 (1974).
Patents Abstracts of Japan, abstract of JP-5-202047 A (Chugai Pharmaceut. Co. Ltd.) Aug. 10, 1993.
Sato et al., “Psychotropic agents, 3, 4-(4-Substituted piperidinyl)-1-(4-flurophenyl)-1-butanones with potent neuroleptic activity”, CAPLUS 89:208915 (1978).
Sato et al., “Psychotropic Agents. 3.l4-(4-Substituted piperidinyl)-1-(4-flurophenyl)-1-butanones with Potent Neuroleptic Activity,”Journal of Medicinal Chemistry21(11):1116-1120 (1978).
Taylor et al., “Molecular Determinants for Recognition of RU 24969 Analogs at Central 5-Hydroxytryptamine Recognition Sites: Use of a Bilinear Function and Substituent Volumes to Describe Steric Fit,”Molecular Pharmacology32:42-53 (1988).
Teranishi et al., “Piperidine derivatives and pharmaceutical compositions containing them”, CAPLUS 95:132947 (1981).
Vandenberk et al., “1-(Benzazolylalkyl)piperidines and their salts with acids”, CAPLUS 87:23274 (1977).
Vartanyan et al., “Synthesis and biological activity of 1-substituted benzimidazole and benztriazole derivatives”, CAPLUS 98:4503 (1983).
Bonnert Roger
Cage Peter
Hunt Fraser
Jewell Robert
Walters Iain
AstraZeneca AB
Fish & Richardson P.C.
McKenzie Thomas C.
LandOfFree
Thiazolopyrimidines and their use as modulators of chemokine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiazolopyrimidines and their use as modulators of chemokine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazolopyrimidines and their use as modulators of chemokine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3483691